Reaction

Ear Congestion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,668 reports · 66 co-occurring drugs

As of the last recalculation, Ear Congestion appears in 2,668 FAERS reports alongside 66 co-occurring drug terms. The strongest observed disproportionality signal is DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS (PRR 22.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Diltiazem Hydrochloride Extended-Release Tablets	32	22.2	22.3
Mometasone	42	18.1	18.2
Omalizumab	128	12.3	12.3
Epoprostenol	20	12.0	12.0
Mometasone Furoate	56	10.7	10.7
Theophylline	15	10.2	10.2
Theophylline Anhydrous	16	10.1	10.1
Zinc Gluconate	32	9.7	9.7
Zinc	30	9.6	9.6
Zinc Chloride	30	9.5	9.5
Selexipag	31	9.5	9.5
Cephalexin	26	9.5	9.5
Diltiazem Hydrochloride	38	8.7	8.7
Metformin Hydrochloride Tablets	60	8.3	8.3
Metformin Hydrochloride Extended-Release Tablets	60	8.3	8.3
Metformin Hydrochloride Tablet	60	8.3	8.3
Metformin Hydrochloride	60	8.1	8.1
Macitentan	62	7.1	7.1
Methimazole	7	7.0	7.0
Thyroid, Porcine	9	6.6	6.6
Cholestyramine	10	6.5	6.5
Atorvastatin Calcium, Film Coated	56	6.3	6.3
Ambrisentan	96	6.2	6.2
Loratadine Tablet	39	5.7	5.7
Tadalafil	71	5.7	5.7
Treprostinil	87	5.6	5.6
Selinexor	6	5.4	5.4
Fexofenadine Hydrochloride	15	5.4	5.4
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	34	5.4	5.4
Avapritinib	8	5.2	5.2
Riociguat	21	5.1	5.1
Sildenafil	37	5.0	5.0
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	13	4.9	5.0
Naproxen Sodium, Pseudoephedrine Hydrochloride	13	4.9	4.9
Triamcinolone Acetonide	19	4.8	4.8
Progesterone	14	4.8	4.8
Piperacillin Sodium,Tazobactam Sodium	16	4.7	4.7
Brinzolamide	5	4.5	4.5
Fluticasone Furoate And Vilanterol Trifenatate	20	4.4	4.4
Loratadine	59	4.4	4.4
Rifampin	8	4.3	4.3
Amikacin	9	4.1	4.1
Vibegron	4	3.9	3.9
Calcium, Magnesium, Potassium, And Sodium Oxybates	4	3.6	3.6
Vedolizumab	38	3.5	3.5
Abaloparatide	13	3.5	3.5
Linaclotide	11	3.2	3.2
Cortisone Acetate	5	3.2	3.2
Etanercept	228	3.2	3.2
Botulinum Toxin Type A	5	3.1	3.1
Asfotase Alfa	4	3.1	3.1
Nirmatrelvir And Ritonavir	18	2.6	2.6
Ofatumumab	11	2.6	2.6
Eptinezumab-Jjmr	3	2.6	2.6
Evolocumab	52	2.5	2.5
Ocrelizumab	20	2.5	2.5
Teriflunomide	12	2.1	2.1
Axitinib	5	2.0	2.0
Benralizumab	5	2.0	2.0
Cenegermin-Bkbj	3	1.9	1.9
Natalizumab	44	1.9	1.9
Erenumab-Aooe	12	1.7	1.7
Sarilumab	5	1.5	1.5
Ixekizumab	7	1.5	1.5
Apremilast	25	1.3	1.3
Dupilumab	81	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.